CLINICAL TRIALS PROFILE FOR DOPTELET
✉ Email this page to a colleague
All Clinical Trials for doptelet
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04312789 ↗ | Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant | Recruiting | Dova Pharmaceuticals | Phase 2 | 2020-08-10 | This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets. |
| NCT04312789 ↗ | Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant | Recruiting | National Cancer Institute (NCI) | Phase 2 | 2020-08-10 | This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets. |
| NCT04312789 ↗ | Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant | Recruiting | Basem William, MD | Phase 2 | 2020-08-10 | This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets. |
| NCT04312789 ↗ | Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant | Recruiting | Ohio State University Comprehensive Cancer Center | Phase 2 | 2020-08-10 | This phase II trial studies the side effects and how well avatrombopag works for the treatment of thrombocytopenia after donor hematopoietic stem cell transplant. Thrombocytopenia is defined as abnormally low level of platelets in the blood. Avatrombopag is a small molecule thrombopoietin receptor agonist which stimulates thrombopoietin receptor leading to increase production of platelets. |
| NCT04516967 ↗ | Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months | Recruiting | Dova Pharmaceuticals | Phase 3 | 2021-03-02 | A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months |
| NCT04845659 ↗ | Avatrombopaq In Patients With Cirrhosis | Not yet recruiting | Hvidovre University Hospital | Phase 4 | 2021-06-01 | Thrombocytopenia is a frequent issue in patients with cirrhosis undergoing various types of procedures (e.g. liver biopsy, endoscopy and minor surgical interventions). Thrombocytopenia < 50*10^9/L increases the risk of perioperative and postoperative bleedning and might prevent patients with cirrhosis to undergo important procedures. Doptelet is a small molecular trombopoetin agonist, which results in proliferation and differentiation of megakaryocytes in the bone marrow resulting in increased levels of thrombocytes. It is given orally as a pill and is used to increase platelet count in patients with severe thrombocytopenia (< 50*10^9/L) and cirrhosis and thus not to normalize platelet count. This study investigates the safety and efficacy of Doptelet in patients with cirrhosis and thrombocytopenia (< 50*10^9/L) undergoing minor procedures like Transjugular Adjusted Liver Biopsy (TJALB) and gastroscopy. |
| NCT04915287 ↗ | Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure | Recruiting | Chinese PLA General Hospital | Phase 4 | 2021-06-06 | In this study, investigators aimed to evaluate the efficacy of Avatrombopag in thrombocytopenic patients with chronic liver disease undergoing an elective invasive procedure through a prospective, non-randomized controlled, multicenter clinical trial. The patients were non-randomly assigned to the Avatrombopag group (119 patients) and the conventional treatment group (357 patients). The primary endpoint was the proportion of patients not requiring prophylactic platelet transfusion or rescue therapy due to bleeding from grouping up to 10 days post-procedure. Second endpoints included the proportion of patients achieving a platelet count of ≥50x10^9/L and the mean change in platelet count from baseline at the time before the procedure, the proportion of patients requiring platelet transfusion and the mean platelet transfusion units per capita, the incidence of bleeding events (WHO≥2 and requiring rescue therapy), the imaging evaluations of bleeding events, the incidence of adverse events, the changes in life quality between two groups before and after treatment, and the pharmacoeconomic index of two groups. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for doptelet
Condition Name
Clinical Trial Locations for doptelet
Trials by Country
Clinical Trial Progress for doptelet
Clinical Trial Phase
Clinical Trial Sponsors for doptelet
Sponsor Name
